STTK

4.4502.20%
AN

Arunthathy Nirmalini Pandite

Chief Medical Officer

Dr. Arunthathy Nirmalini Pandite, also known as Lini, MBChB, M.D., MBA, has served as Director of Codiak BioSciences, Inc. since August 2021 and served as its Independent Director until July 2023. She has been Chief Medical Officer of Shattuck Labs, Inc. since July 2017. From May2015 to June 2017, Dr. Pandite served as Head of Global Clinical Development and Senior Vice President at Adaptimmune Therapeutics plc. Dr. Pandite has academic, medical and pharmaceutical experience. From May2001 to April 2015, Dr. Pandite served in GlaxoSmithKline (GSK) culminating in her tenure as Head Unit Physician, Oncology R&D, Vice President. While there, she was instrumental in leading the development of several compounds, including Votrient® (pazopanib), from the first study in humans through marketing authorization and commercialization of its approved indications. She has strong experience in oncology drug development spanning early to late phase, including clinical trial design, regulatory interactions, and clinical risk management. Dr. Pandite has practiced medicine in both the U.K. and U.S. and is Board certified in hematology and oncology. Dr. Pandite was an attending physician at Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami from January 1998 to November 2000 and at Dana Farber Cancer Institute in Boston from July 1993 to August 1996 and has held academic appointments at Harvard University and the University of Miami. She earned her MBChB from The University of Liverpool, England and her M.B.A. from Duke University.

Positions